Shares of Natco Pharma have witnessed a sharp 30% decline in just two days following the release of its weak Q3 FY25 earnings. Today, As of 9:37 AM, the shares were trading 8.85% lower at Rs 888.80.
The pharmaceutical company’s consolidated net profit fell to ₹133 crore in the quarter ending December 31, 2024, a steep drop from ₹212.7 crore in the same period last year.
The revenue also took a significant hit, declining by 37.4% to ₹474.8 crore from ₹758.6 crore in Q3 FY24. Additionally, EBITDA plummeted 86% to ₹38.79 crore, compared to ₹268.1 crore in the year-ago quarter, reflecting a sharp decline in operational performance. Margins narrowed drastically to 8.2% in Q3 FY25, down from 35.3% in the previous year.
Natco Pharma’s shares opened today at ₹950.00, hitting a high of ₹950.00 and a low of ₹875.20. The stock remains volatile, nearing its 52-week low of ₹848.05, significantly down from its 52-week high of ₹1,639.00.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
